Drug Status Report

**Drug:** PF514273

**Drug Name Status:** PF514273 is the common name.

**Chemical Name:** 2-(2-Chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one

**Chemical structure:**

![Chemical Structure](image)

**Molecular Formula:** $C_{21}H_{17}ClF_2N_3O_2$

**Pharmacological class / Application:** Cannabinoid CB$_1$ receptor antagonist

**International status:**

US: The substance is not listed on the schedules to the CSA and is not mentioned on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control. The drug is not listed on the Green List - List of Psychotropic Substances under International Control.

Canadian Status: PF514273 was among a number of compounds that were developed by Pfizer and as selective cannabinoid CB$_1$ receptor antagonists. PF514273 has been shown to display significantly greater selectivity for the CB$_1$ receptor compared to the CB$_2$ receptor and demonstrate potent CB$_1$ receptor antagonist activity in functional assays. Cannabinoid receptor agonists have been declared to be included within item 1 of Schedule II to the CDSA by virtue of being “similar synthetic preparations.” Cannabinoid receptor antagonists have been declared to fall outside item 1 of Schedule II to the CDSA. Given that PF514273 is potent cannabinoid receptor antagonist, the substance should not be included in item 1 of Schedule II.

**Recommendation:** PF514273 is not included in Schedule II to the CDSA and is a not controlled substance.

January 7th, 2010

---
